Table 1. Baseline characteristics of MDR-TB patients on treatment, LFU and non-LFU patients at Drug Resistant TB Centre in Vadodara, Gujarat, India.
| Variables | Entire Cohort* | LFU* | Non-LFU* |
|---|---|---|---|
| N(%) | N(%) | N (%) | |
| Age (years) Median (IQR) | 35 (27–45) | 35 (28–45) | 35 (27–45) |
| Weight (kg) Median (IQR) | 39 (34–45) | 40 (35–45) | 39 (34–45) |
| Male Sex | 571/794 (71.9) | 114/153 (74.5) | 457/641 (71.3) |
| Rural residence | 352/794 (44.3) | 64/153(41.8) | 288/641 (44.9) |
| Below poverty line | 614/794 (77.3) | 120/153 (78.4) | 494/641 (77.1) |
| Previous TB treatment | 362/794 (45.8) | 78/153 (51.3) | 284/641 (44.3) |
| Duration of previous treatment >2 years | 44/268 (16.4) | 52/59 (88.1) | 37/209 (17.7) |
| Same DOT Provider in IP and CP | 408/507 (80.5) | 23/153 (15.0) | 385/479 (80.4) |
| HIV infected | 10/793 (01.3) | 01/153(0.7) | 9/640 (01.4) |
| Chest X-Ray Bilateral involvement | 610/716 (85.2) | 114/132(86.4) | 496/584 (84.9) |
| Chest X-ray Cavitation | 343/716 (47.9) | 58/132(43.9) | 285/584 (48.8) |
| Ambulatory initiation of treatment | 65/794 (08.2) | 20/153(13.1) | 45/641 (07.0) |
| Adverse events in IP | 151/793 (19.0) | 30/153(19.6) | 121/640 (18.9) |
| Adverse events in CP | 34/793 (04.3) | 01/20(05.0) | 33/640 (05.2) |
| Culture conversion time(days) Median (IQR) | 105 (93–147) | 153.75 (104–180.7) | 105.5 (93–149.5) |
| Duration of MDR treatment before outcome(days) Median (IQR) | 361 (137–739) | 142 (63.5–296) | 531 (229–759.75) |
*Number varies according to data available from records IQR-Inter Quartile Range; DOT-Direct Observed Treatment; IP- Intensive Phase; CP-Continuation Phase.